Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.

Pedro Mezquita-RayaAntonio Ramírez de ArellanoNana KraghGabriela Vega-HernandezJohannes PöhlmannWilliam J ValentineBarnaby Hunt

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2017)

Long-term projections in the Spanish setting suggest that liraglutide 1.8 mg is likely to be cost-effective compared with lixisenatide 20 μg in type 2 diabetes patients who have not achieved glycemic control targets on metformin monotherapy. Liraglutide 1.8 mg presents a clinically and economically attractive treatment option in the Spanish setting.

Keyphrases

type diabetes
glycemic control
end stage renal disease
chronic kidney disease
combination therapy
blood glucose
newly diagnosed
ejection fraction
cardiovascular disease
randomized controlled trial
metabolic syndrome
weight loss
adipose tissue
skeletal muscle
open label
study protocol